Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/ A39V) in a murine model of ischaemic stroke

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Andreou, Anna P ^a   Efthymiou, Maria ^a   Yu, Yao ^a   Watts, Helena R ^a   Noormohamed, Faruq H ^a   Ma, Daqing ^a   Lane, David A ^a   Crawley, James T B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ACTIVATED PROTEIN C (36 39); ACTIVATED PROTEIN C (5A); ACTIVATED PROTEIN C (CA INS); ANTICOAGULANT AGENT; HEMATOLOGIC AGENT; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN C;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SECRETION; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; HEK293 CELL LINE; HUMAN; INFARCTION, MIDDLE CEREBRAL ARTERY; KINETICS; METABOLISM; MISSENSE MUTATION; PRECLINICAL STUDY; REPERFUSION INJURY; THROMBIN TIME;

MURINAE;

ANIMALS; ANTICOAGULANTS; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; KINETICS; MALE; MICE, INBRED C57BL; MUTATION, MISSENSE; NEUROPROTECTIVE AGENTS; PROTEIN C; PROTEIN C INHIBITOR; PROTEOLYSIS; REPERFUSION INJURY; THROMBIN; THROMBIN TIME;

EID: 84926442457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122410     Document Type: Article

References (43)

1. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL (2009) Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke 40: 2079-2084. doi: 10.1161/STROKEAHA.108. 540708 PMID: 19372447
2. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA (2000) Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283: 1145-1150. PMID: 10703776
3. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 5: 1732-1739. PMID: 17596135
4. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4: 228-231. PMID: 9461198
5. Bouwens EA, Stavenuiter F, Mosnier LO (2013) Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 11 Suppl 1: 242-253. doi: 10.1111/jth.12247 PMID: 23809128
6. Zhang L, Jhingan A, Castellino FJ (1992) Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood 80: 942-952. PMID: 1498334
7. Gale AJ, Tsavaler A, Griffin JH (2002) Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem 277: 28836-28840. PMID: 12063259
8. Bae JS, Yang L, Manithody C, Rezaie AR (2007) Engineering a disulfide bond to stabilize the calciumbinding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J Biol Chem 282: 9251-9259. PMID: 17255099
9. Preston RJ, Ajzner E, Razzari C, Karageorgi S, Dua S, Dahlback B, et al. (2006) Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem 281: 28850-28857. PMID: 16867987
10. Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109: 3161-3172. PMID: 17110453
11. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH (2012) Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 120: 5237-5246. doi: 10.1182/blood-2012-08-452169 PMID: 23149848
12. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, et al. (2006) Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 12: 1278-1285. PMID: 17072311
13. Liu D, Cheng T, Guo H, Fernandez JA, Griffin JH, Song X, et al. (2004) Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 10: 1379-1383. PMID: 15516929
14. Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, et al. (2012) An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke 43: 2444-2449. doi: 10.1161/STROKEAHA.112.658997 PMID: 22811462
15. Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernandez JA, et al. (2009) Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci 29: 1119-1130. doi: 10. 1111/j.1460-9568.2009.06664.x PMID: 19302148
16. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709. PMID: 11236773
17. Mosnier LO, Yang XV, Griffin JH (2007) Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 282: 33022-33033. PMID: 17872949
18. Harmon S, Preston RJ, Ni Ainle F, Johnson JA, Cunningham MS, Smith OP, et al. (2008) Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem 283: 30531-30539. doi: 10.1074/jbc.M802338200 PMID: 18779332
19. Lyden P, Levy H, Weymer S, Pryor K, Kramer W, Griffin JH, et al. (2013) Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des 19: 7479-7485. PMID: 24372304
20. Preston RJ, Villegas-Mendez A, Sun YH, Hermida J, Simioni P, Philippou H, et al. (2005) Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation. Febs J 272: 97-108. PMID: 15634335
21. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH (2004) Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104: 1740-1744. PMID: 15178575
22. Yan SC, Razzano P, Chao YB, Walls JD, Berg DT, McClure DB, et al. (1990) Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology (N Y) 8: 655-661. PMID: 1366628
23. Zhang L, Castellino FJ (1990) A gamma-carboxyglutamic acid (gamma) variant (gamma 6D, gamma7D) of human activated protein C displays greatly reduced activity as an anticoagulant. Biochemistry 29: 10828-10834. PMID: 2125495
24. Yang L, Manithody C, Rezaie AR (2002) Contribution of basic residues of the 70-80-loop to heparin binding and anticoagulant function of activated protein C. Biochemistry 41: 6149-6157. PMID: 11994010
25. Lopez-Sagaseta J, Montes R, Hermida J (2009) Recombinant expression of biologically active murine soluble EPCR. Protein Expr Purif 64: 194-197. doi: 10.1016/j.pep.2008.11.002 PMID: 19041722
26. Friedrich U, Blom AM, Dahlback B, Villoutreix BO (2001) Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem 276: 24122-24128. PMID: 11316800
27. Li W, Adams TE, Nangalia J, Esmon CT, Huntington JA (2008) Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex. Proc Natl Acad Sci U S A 105: 4661-4666. doi: 10.1073/pnas.0711055105 PMID: 18362344
28. Berg DT, Gerlitz B, Shang J, Smith T, Santa P, Richardson MA, et al. (2003) Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A 100: 4423-4428. PMID: 12671072
29. Ahnstrom J, Andersson HM, Hockey V, Meng Y, McKinnon TA, Hamuro T, et al. (2012) Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Blood 120: 5059-5062. doi: 10.1182/blood-2012-05-432005 PMID: 23074276
30. Ahnstrom J, Andersson HM, Canis K, Norstrom E, Yu Y, Dahlback B, et al. (2011) Activated protein C cofactor function of protein S: a novel role for a gamma-carboxyglutamic acid residue. Blood 117: 6685-6693. doi: 10.1182/blood-2010-11-317099 PMID: 21508412
31. Homi HM, Yokoo N, Ma D, Warner DS, Franks NP, Maze M, et al. (2003) The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology 99: 876-881. PMID: 14508320
32. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR (1990) A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10: 290-293. PMID: 1689322
33. Choudhri TF, Hoh BL, Solomon RA, Connolly ES Jr., Pinsky DJ (1997) Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke 28: 2296-2302. PMID: 9368579
34. Thiyagarajan M, Fernandez JA, Lane SM, Griffin JH, Zlokovic BV (2008) Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci 28: 12788-12797. doi: 10.1523/JNEUROSCI.3485-08.2008 PMID: 19036971
35. Wang J, Rogove AD, Tsirka AE, Tsirka SE (2003) Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage. Ann Neurol 54: 655-664. PMID: 14595655
36. Riewald M, Petrovan RJ, Donner A, Mueller BM, RufW(2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296: 1880-1882. PMID: 12052963
37. Guo H, Wang Y, Singh I, Liu D, Fernandez JA, Griffin JH, et al. (2009) Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem 109: 116-124. doi: 10.1111/j.1471-4159.2009.05921.x PMID: 19166505
38. Sen P, Clark CA, Gopalakrishnan R, Hedner U, Esmon CT, Pendurthi UR, et al. (2012) Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems. Thromb Haemost 107: 951-961. doi: 10.1160/TH11-09-0672 PMID: 22370814
39. Fernandez JA, Heeb MJ, Xu X, Singh I, Zlokovic BV, Griffin JH (2009) Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica 94: 1721-1731. doi: 10.3324/haematol. 2009.009233 PMID: 19815836
40. Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, et al. (1990) Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost 63: 48-53. PMID: 2140205
41. Shen L, Dahlback B, Villoutreix BO (2000) Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin. Biochemistry 39: 2853-2860. PMID: 10715104
42. Glasscock LN, Gerlitz B, Cooper ST, Grinnell BW, Church FC (2003) Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by alpha(1)-antitrypsin. Biochim Biophys Acta 1649: 106-117. PMID: 12818196
43. Ni Ainle F, O'Donnell JS, Johnson JA, Brown L, Gleeson EM, Smith OP, et al. (2011) Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. J Biol Chem 286: 1323-1330. doi: 10.1074/jbc.M110.159475 PMID: 21044954